Potential of an LRG1-Targeting Degrader in Combating Aggressive Triple-Negative Breast Cancer

Abstract Triple-negative breast cancer (TNBC) remains clinically challenging due to its aggressive phenotype and the scarcity of druggable targets. Leucine-rich alpha-2-glycoprotein 1 (LRG1) is a critical driver of TNBC progression, yet its has precluded the development of conventional occupancy-driven inhibitors. In this study, we employed an event-driven proteolysis-targeting chimera (PROTAC) strategy to target this “undruggable” LRG1 for degradation. Leveraging our previously developed ETTAC-2─a peptide-based PROTAC with established efficacy in ocular neovascularization and renal fibrosis models─we demonstrate that this degrader induces effective LRG1 degradation via the ubiquitin-proteasome system in a dose- and time-dependent manner in 4T1 TNBC cells. Mechanistically, ETTAC-2-mediated degradation of LRG1 suppressed the p-AKT and HIF-1α signaling axes, impairing cell proliferation in vitro and orchestrating a robust antitumor response in vivo. Systemic administration of ETTAC-2 significantly attenuated mammary tumor growth and impeded the aggressive phenotype by reversing the epithelial-mesenchymal transition (EMT) program through sustained inhibition of HIF-1α signaling. By effectively reversing EMT markers and curtailing the malignant progression of TNBC without observable systemic toxicity, our findings validate LRG1 as a viable therapeutic target and establish ETTAC-2 as a pioneering lead compound that bypasses structural limitations to treat recalcitrant breast cancers.

Authors

Institutions

Publication Details

Journal
ACS Omega
Published
2026-11-12
DOI
https://doi.org/10.1021/acsomega.6c07595
Primary Topic
Protein Degradation and Inhibitors
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Potential of an LRG1-Targeting Degrader in Combating Aggressive Triple-Negative Breast Cancer

Shiyu Song, Yingqiu Qi, Huan Min, Yao Li et al.
ACS Omega
Protein Degradation and Inhibitors
article

Potential of an LRG1-Targeting Degrader in Combating Aggressive Triple-Negative Breast Cancer

Shiyu Song, Yingqiu Qi, Huan Min, Yao Li, Xiaoming Zhu, Furong Zhu, Yating Wang, Yu Li, Yongzheng Li
article en

Abstract

Abstract Triple-negative breast cancer (TNBC) remains clinically challenging due to its aggressive phenotype and the scarcity of druggable targets. Leucine-rich alpha-2-glycoprotein 1 (LRG1) is a critical driver of TNBC progression, yet its has precluded the development of conventional occupancy-driven inhibitors. In this study, we employed an event-driven proteolysis-targeting chimera (PROTAC) strategy to target this “undruggable” LRG1 for degradation. Leveraging our previously developed ETTAC-2─a peptide-based PROTAC with established efficacy in ocular neovascularization and renal fibrosis models─we demonstrate that this degrader induces effective LRG1 degradation via the ubiquitin-proteasome system in a dose- and time-dependent manner in 4T1 TNBC cells. Mechanistically, ETTAC-2-mediated degradation of LRG1 suppressed the p-AKT and HIF-1α signaling axes, impairing cell proliferation in vitro and orchestrating a robust antitumor response in vivo. Systemic administration of ETTAC-2 significantly attenuated mammary tumor growth and impeded the aggressive phenotype by reversing the epithelial-mesenchymal transition (EMT) program through sustained inhibition of HIF-1α signaling. By effectively reversing EMT markers and curtailing the malignant progression of TNBC without observable systemic toxicity, our findings validate LRG1 as a viable therapeutic target and establish ETTAC-2 as a pioneering lead compound that bypasses structural limitations to treat recalcitrant breast cancers.

ACS Omega
Macau University of Science and Technology (MO), Zhejiang Sci-Tech University (CN), Zhengzhou University (CN)
Henan Provincial Science and Technology Research Project
Good health and well-being
Protein Degradation and Inhibitors
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon